

Carme Font

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4094283/publications.pdf>

Version: 2024-02-01

43
papers

1,756
citations

471509

17
h-index

276875

41
g-index

50
all docs

50
docs citations

50
times ranked

1814
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
2	Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. <i>Arthritis and Rheumatism</i> , 1998, 41, 26-32.	6.7	255
3	Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. <i>Arthritis and Rheumatism</i> , 2000, 43, 184-194.	6.7	128
4	Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. <i>Arthritis and Rheumatism</i> , 2001, 44, 1387-1395.	6.7	105
5	Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2002, 106, 1664-1671.	1.6	99
6	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. <i>American Journal of Medicine</i> , 2017, 130, 337-347.	1.5	83
7	Large vessel vasculitides. <i>Current Opinion in Rheumatology</i> , 1998, 10, 18-28.	4.3	78
8	Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 1998, 41, 435-444.	6.7	56
9	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. <i>Medicine (United States)</i> , 2016, 95, e2368.	1.0	55
10	Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EIPHANY study. <i>European Respiratory Journal</i> , 2017, 49, 1600282.	6.7	52
11	Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 83-89.	4.4	45
12	Outpatient Management of Pulmonary Embolism in Cancer: Data on a Prospective Cohort of 138 Consecutive Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 365-373.	4.9	38
13	Solid cancer, antiphospholipid antibodies, and venous thromboembolism. <i>Autoimmunity Reviews</i> , 2011, 10, 222-227.	5.8	33
14	Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS). <i>Supportive Care in Cancer</i> , 2018, 26, 3233-3239.	2.2	25
15	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 48, 1360-1368.	6.7	21
16	A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study. <i>Cancers</i> , 2020, 12, 75.	3.7	20
17	Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. <i>Supportive Care in Cancer</i> , 2021, 29, 1129-1138.	2.2	20
18	Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. <i>Heliyon</i> , 2017, 3, e00229.	3.2	19

#	ARTICLE	IF	CITATIONS
19	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 21930-21937.	1.8	17
20	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2018, 13, e0194673.	2.5	16
21	High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. <i>European Journal of Cancer</i> , 2020, 141, 193-198.	2.8	15
22	A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. <i>British Journal of Cancer</i> , 2016, 114, 1191-1198.	6.4	14
23	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Tj ETQq1 1 0.784314 rgBT /Overlock 10) 2019, 45, 793-801.	2.7	12
24	Thrombosis, cancer, and COVID-19. <i>Supportive Care in Cancer</i> , 2022, 30, 8491-8500.	2.2	10
25	Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study. <i>European Journal of Radiology</i> , 2017, 87, 66-75.	2.6	9
26	Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. <i>Supportive Care in Cancer</i> , 2022, 30, 2919-2931.	2.2	8
27	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e210-e217.	1.4	7
28	Comparing low-molecular-weight heparin dosing for treatment of venous thromboembolism in patients with obesity (RIETE registry). <i>Blood Advances</i> , 2020, 4, 2460-2467.	5.2	7
29	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 489-495.	1.7	6
30	Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmb3lica (RIETE) registry. <i>British Journal of Haematology</i> , 2021, 194, 195-199.	2.5	6
31	Reply. <i>Arthritis and Rheumatism</i> , 1998, 41, 2088-2089.	6.7	5
32	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. <i>Scientific Reports</i> , 2019, 9, 20064.	3.3	5
33	Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. <i>Supportive Care in Cancer</i> , 2022, 30, 8599-8609.	2.2	5
34	Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1119-1122.	3.4	4
35	Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis. <i>Cancers</i> , 2021, 13, 2517.	3.7	3
36	Mortality in patients treated for COVID-19 in the emergency department of a tertiary care hospital during the first phase of the pandemic: Derivation of a risk model for emergency departments. <i>Emergencias</i> , 2021, 33, 273-281.	0.6	2

#	ARTICLE	IF	CITATIONS
37	A nomogram for predicting serious complications in patients with solid tumors and apparently stable febrile neutropenia: Prospective data on 781 consecutive episodes from the FINITE study.. Journal of Clinical Oncology, 2014, 32, 165-165.	1.6	1
38	Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Internal and Emergency Medicine, 2021, , 1.	2.0	1
39	Risk stratification for clinical severity of pulmonary embolism in patients with cancer: a narrative review and MASCC clinical guidance for daily care. Supportive Care in Cancer, 2022, , 1.	2.2	1
40	Edoxaban for the Longâ€Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?. Clinical and Translational Science, 2021, 14, 335-342.	3.1	0
41	Prediction of major complications in patients with solid tumors and apparently stable febrile neutropenia: Validation of the CISNE risk score.. Journal of Clinical Oncology, 2014, 32, 9620-9620.	1.6	0
42	Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive patients from the EPIPHANY study.. Journal of Clinical Oncology, 2014, 32, 9526-9526.	1.6	0
43	Development and validation of a Clinical Index of Severe Febrile Neutropenia: A prospective multicenter study.. Journal of Clinical Oncology, 2015, 33, 9617-9617.	1.6	0